One of the issues with BAC is that I've referred to it as potentially very indolent, but as we've learned more about BAC, it's become clear that there is a great degree of heterogeneity in BAC cases. We're learning that the cases that are more often slowly progressing and sometimes exceptionally responsive to EGFR inhibitors like tarceva and iressa are far more likely to be non-mucinous BAC. These typically have the appearance of innumerable small nodules throughout the lungs.